A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Phase 1

Terminated

• Conditions: Non Small Cell Lung Cancer
• Interventions: Drug: Belinostat and Erlotinib

• Registration Number: NCT01188707
• Lead Sponsor: Herlev Hospital

Brief Summary

The Belinostat-Erlotinib trial is designed as an open, non randomized phase I / II trial to assess the efficacy and safety of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer who are eligible for treatment with erlotinib.

Detailed Description

Belinostat, developed by CuraGen, belongs to a new class of hydroxymat-type histone deacetylase (HDAC) inhibitors. HDAC inhibitors, including Belinostat, has shown marked in vitro and in vivo activity against a number of solid tumors and hematological cancers. Belinostat has proven to be effective as a single agent or in combination with other anticancer agents such as doxorubcin, paclitaxel, carboplatin, fluorouracil, bortezumib, and there has been observed synergy between Belinostat or other HDAC inhibitors and EGFR inhibitors gefinitinib and erlonitib.

Furthermore, the antineoplastic activity of Belinostat seen in preclinical experiments have resulted in only moderate toxicity.

In the two Phase I trials of Belinostat for solid tumors and hematological malignancies Belinostat have been well tolerated at doses up to 2000 mg daily in more than 100 patients.

Fatigue, nausea and vomiting has been the main side effects and with none or very mild hematologic toxicity. Approximately 25% of patients in the study of solid tumors achieved stable disease.

Study Timeline

• Study First Submitted: 2010-08-24
• Study First Submitted QC: 2010-08-24
• Study First Posted: 2010-08-25
• Study Start: 2010-10-01
• Primary Completion: 2011-06-30
• Study Completion: 2011-06-30
• Status Verified: 2020-10
• Last Update Submitted: 2020-10-16
• Last Update Posted: 2020-10-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

1. Signed consent of an approved informed consent form

2. A. For the dose escalation phase: Patients with histological or cytological confirmed non-small cell lung cancer who are rated suitable for treatment with Erlotinib B. For MTD expansion phase: Patients diagnosed with non- small cell lung cancer rated suitable for treatment with Erlotinib and with measurable disease according to RECIST version 1.1

3. Performance status (ECOG) ≤ 2

4. Life expectancy at least 3 months

5. Age ≥ 18 years

6. Acceptable liver, kidney and bone marrow function, defined as:

   • Bilirubin ≤ 1.5 x upper limit of normal (ULN)
   • ASAT, ALAT and alkaline phosphatase ≤ 3 x ULN (if liver metastases is ≤ 5 x ULN allowed)
   • Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
   • WBC> 2.5 x 109 / l, neutrophils> 1.0 x 109 / l, platelets> 100 x 109 / l
   • Hemoglobin> 9.0 g / dl or> 5.6 mmol / l

7. Acceptable coagulation: PT and APTT within ≤ 1.5 x ULN or in the therapeutic range if given anticoagulant

8. A negative pregnancy test for women of childbearing age. In fertile men and women the use of effective contraception methods are required during the trial

9. Serum potassium within normal range

Exclusion Criteria

1. Treatment with experimental drugs within the last 4 weeks
2. Former anti-cancer therapy within the last 3 weeks before the start of experimental treatment, including chemotherapy, radiotherapy, endocrine therapy or immunotherapy
3. Simultaneous presence of active infection or other concomitant present medical condition likely to affect the experimental procedures, including significant cardiovascular disease (New York Heart Association Class III or IV heart disease, myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring treatment, unstable arrhythmia or the need for antiarrhythmic drugs or signs of ischemia on ECG, marked baseline prolongation of QT / QTc interval, for example repeated demonstration of a QTc interval> 500 msec; long QT syndrome; required the use of concurrent medication on dosage belinostat days, which may cause torsades de pointes (see Appendix 1).
4. Altered mental status that prevents understanding of the informed consent process and / or execution of the necessary experiments
5. Secondary malignancy present (previous malignancy accepted if cured by treatment for > 3 years ago)
6. Intestinal obstruction or threatening bowel obstruction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Belinostat, Erlotinib, NSCLC	Belinostat and Erlotinib	-

Primary Outcome Measures

Name	Time	Method
Safety	1 year	The primary purpose of the phase I part of the trial is to establish the tolerance dose (maximum tolerated dose (MTD) and dose limiting toxicity (DLT).

Secondary Outcome Measures

Name	Time	Method
Efficacy	1 year	The phase II part of the study is to assess the efficacy of Belinostat and Erlotinib in combination assessed by disease control rate, defined as non - progression at 3 months / Stable disease or better) using RECIST response criteria version 1.1

Trial Locations

Locations (1)

Dept of Oncology Copenhagen University Hospital Herlev; 🇩🇰 Copenhagen, Denmark